Odanacatib
From Wikipedia, the free encyclopedia
 |
|
|
Odanacatib
|
|
| Systematic (IUPAC) name | |
| (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl- 2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)- [1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C25H27F4N3O3S |
| Mol. mass | 525.56 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis. It is an inhibitor of cathepsin K,[1] an enzyme involved in bone resorption.
It is being developed by Merck & Co. As of May 2008, Merck is conducting phase III clinical trials.
[edit] References
- ^ Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC. (2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg Med Chem Lett. 18 (3): 923-928. doi:.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
